Upper Tract Urothelial Carcinoma
Advertisement
A team of researchers set out to determine the preferred sequence of perioperative systemic therapy for node-positive UTUC.
Yair Lotan, MD, details the real-world use, effectiveness, and standard-of-care potential of UGN-101 for patients with UTUC.
Dr. Coleman shares his unique career path, his role in defining UTUC, and ongoing research to improve patient outcomes.
Intracorporeal DUBC may be a safe and effective alternative to RNU for UTUC, according to a new research.
Neoadjuvant chemotherapy with gemcitabine and split-dose cisplatin is well-tolerated and effective in patients with UTUC.
A delay in definitive radical cystectomy or radical nephro-ureterectomy is associated with poor survival in UTUC patients.
A research team recently investigated the use of tubular damage biomarkers as prognostic markers for upper tract UC.
Up to one-third of all UTUC patients present with variant histology, such as squamous or micropapillary features.
1 of 4 will UTUC patients will have a variant histologic subtype such as squamous cell, micropapillary, or neuroendocrine.
Out of 17 studies, adjuvant radiotherapy had no significant effect on UTUC, and radiotherapy had a negative impact on OS.
Among patients with mUTUC, a distant lymph node was the most common site of single-organ metastases.
Since 2006, the surgical technique and the robotic surgical system has gone through a major evolution.
The study examined the construction and verification of a new nomogram established to predict the local recurrence risk.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726